

# PEOPLE



Bioanalytical Systems (BASi; West Lafayette, IN, USA) has announced the addition of **Edward M. Chait** as executive vice president and chief scientific officer. Dr. Chait spent 23 years at DuPont, reaching the position of director of business development and licensing for DuPont's biotechnology and diagnostics division. Subsequent positions include senior vice president of business development and technology at InterGen and president and CEO of PharmaCore. He was most recently CEO of Spectral Genomics.

Dr. Chait has served as an advisor to the Purdue Cancer Center since 2002. Peter Kissinger, chairman and CEO of Bioanalytical Systems, commented, "I am delighted to bring Ed Chait back to West Lafayette where he received his PhD in analytical chemistry from Purdue University. His particular background in discovery life sciences and instruments is of great value for us, and his reputation and relationships in our industry are a definite asset as we take BASi to the next level."

Guava Technologies (Hayward, CA, USA) has named **Lawrence F. Bruder** to the position of president and COO. Mr. Bruder joined Guava Technologies in 2004, and previously held the title of vice president, corporate development and worldwide marketing.

**Thomas A. Davis** has joined GenVec (Gaithersburg, MD, USA) as chief medical officer. Dr. Davis was formerly head, adult hematologic malignancies for the cancer therapeutics evaluation program at the National Cancer Institute, and senior director, clinical sciences at Medarex.

Windber Research Institute (Windber, PA, USA) has named retired brigadier general **Michael Dunn** as chief medical officer to pursue genomic and proteomic research on cancer, cardiac disease and complimentary medicine. Some of General Dunn's previous posts include Walter Reed Army Institute of Research and US Naval Medical Research Unit No. 3, Cairo, Egypt. He has served on the staffs of the Assistant Secretary of Defense (Health Affairs) and as surgeon of the 3d Armored Division in Germany. Additionally, General Dunn is a professor of medicine at the Uniformed Services University of the Health Sciences.

MorphoSys (Martinsried/Munich) has announced the appointments of **Robert Friesen** as director of preclinical development and **Bernhard Erning** as director of treasury and corporate development. Dr. Friesen joins MorphoSys from Dutch biotech company AM-Pharma, where he served as vice president

of research and preclinical development. Dr. Erning was most recently head of equity capital markets for West LB, and formerly executive director of corporate finance for UBS.

Life sciences investment group Abingworth Management (London) has appointed **Tim Haines** as a partner. Mr. Haines was most recently CEO of the Abingworth portfolio company Astex Therapeutics.

Generic drug developer Actavis Group (Hafnarfirdi, Iceland) has announced the appointment of **Mark Keatley** as chief executive of finance, as well as a member of the group's executive board. He joins Actavis from Famar SA, where he had served as chief financial officer since 2002.



**Vic Knauf** has been named chief scientific officer at agbiotech company Arcadia Biosciences (Davis, CA, USA). Dr. Knauf brings more than 25 years of experience in agricultural R&D and product commercialization to Arcadia. He was a founder of Anawah (formerly Tilligen) and has held senior science positions with Monsanto and Calgene.

Dr. Knauf brings more than 25 years of experience in agricultural R&D and product commercialization to Arcadia. He was a founder of Anawah (formerly Tilligen) and has held senior science positions with Monsanto and Calgene.

**Jorge Leon** has joined Orion Genomics (St. Louis, MO, USA) as acting chief scientific officer and vice president of business development. He also joins the company's board of directors. Dr. Leon is currently president of consulting firm Leomics Associates, and

previously served as vice president of applied genomics at Quest Diagnostics.

SCIREX (Horsham, PA, USA) has named **Linda Metcalf** to the position of senior vice president, global clinical trial management. She joins the company from Omnicare Clinical Research, where she served most recently as senior vice president, clinical operations.

**James C. Mullen**, president and CEO of Biogen Idec, has been elected chairman of the board of directors of the Biotechnology Industry Organization (BIO; Washington, DC, USA), succeeding Alkermes CEO **Richard F. Pops**. Mr. Mullen joined Biogen in 1989 and was named CEO in 2000 and chairman in 2002.



TransForm Pharmaceuticals (Lexington, MA, USA) has announced the appointment of **William Pullman** as senior vice president of exploratory development.

Dr. Pullman was most recently senior vice president, global head of clinical and exploratory pharmacology at Sanofi-Aventis.

**Alan Roach** has been appointed head of therapeutics at DanioLabs (Cambridge, UK). Dr. Roach has spent over 30 years in both the biotech sector and in large pharma, including Synthelabo, Reckitt & Coleman, Glaxo and Rhône-Poulenc Rorer/Aventis. He was previously a founding scientist and director of therapeutics at Argenta Discovery.

Quintiles Transnational (Research Triangle Park, NC, USA) has announced the appointment of **Edward Tabor** as executive director, regulatory and technical services. Dr. Tabor joins Quintiles from the US Food and Drug Administration, where he created the antiviral regulatory review program in the 1980s and was most recently associate director for medical affairs in the office of blood research and review, in the Center for Biologics Evaluation and Research (CBER). In addition, Quintiles has named **Kiyotaka Fujii** as president and CEO of Quintiles Transnational Japan KK. He was previously president and CEO of SAP Japan, a subsidiary of SAP, the world's largest business software company.